One study found that decreased expression of combined ER/PR (estrogen receptor/progesterone receptor) was associated with a poorer outcome in endometrial cancer patients, but hormone receptor status alone did not significantly improve mortality prediction (73). Here, ESR1 is linked to endometrial cancer.